Evidence map›Paper›PMID 36930277›Full record

ArticleApplied microbiology and biotechnology2023

AflQ1-Q2 represses lincomycin biosynthesis via multiple cascades in Streptomyces lincolnensis.

Ruida Wang, Tianyu Zhou, Fanjing Kong, Bingbing Hou, Jiang Ye, Haizhen Wu, Huizhan Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. CRISPR-aided genome engineering for secondary metabolite biosynthesis in Streptomyces.Journal of industrial microbiology & biotechnology · 2024
    Review
  6. Article
  7. Article
  8. DeoR regulates lincomycin production in Streptomyces lincolnensis.World journal of microbiology & biotechnology · 2023
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruida WangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Tianyu ZhouState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Fanjing KongState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Bingbing HouState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Jiang YeState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. yyjj413@163.com.
Haizhen WuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. bacterial@126.com.ORCID http://orcid.org/0000-0001-8528-9269
Huizhan ZhangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
East China University of Science and Technology · CN

Funding

National Key Research and Development Program of China 2021YFC2100600National Natural Science Foundation of China 31900059
6 · The paper itself

Abstract

Lincomycin is a broad-spectrum antibiotic and particularly effective against Gram-positive pathogens. Albeit familiar with the biosynthetic mechanism of lincomycin, we know less about its regulation, limiting the rational design for strain improvement. We therefore analyzed two-component systems (TCSs) in Streptomyces lincolnensis, and selected eight TCS gene(s) to construct their deletion mutants utilizing CRISPR/Cas9 system. Among them, lincomycin yield increased in two strains (Δ3900-3901 and Δ5290-5291) while decreased in other four strains (Δ3415-3416, Δ4153-4154, Δ4985, and Δ7949). Considering the conspicuous effect, SLINC_5291-5290 (AflQ1-Q2) was subsequently studied in detail. Its repression on lincomycin biosynthesis was further proved by gene complementation and overexpression. By binding to a 16-bp palindromic motif, the response regulator AflQ1 inhibits the transcription of its encoding gene and the expression of eight operons inside the lincomycin synthetic cluster (headed by lmbA, lmbJ, lmbK, lmbV, lmbW, lmbU, lmrA, and lmrC), as demonstrated by quantitative RT-PCR and electrophoretic mobility shift assays. Besides, the regulatory genes including bldD, glnR, lcbR1, and ramR are also regulated by the TCS. According to the screening towards nitrogen sources, aspartate affects the regulatory behavior of histidine kinase AflQ2. And in return, AflQ1 accelerates aspartate metabolism via ask-asd, asd2, and thrA. In summary, we acquired six novel regulators related to lincomycin biosynthesis, and elucidated the regulatory mechanism of AflQ1-Q2. This highly conserved TCS is a promising target for the construction of antibiotic high-yield strains. KEY POINTS: • AflQ1-Q2 is a repressor for lincomycin production. • AflQ1 modulates the expression of lincomycin biosynthetic and regulatory genes. • Aspartate affects the behavior of AflQ2, and its metabolism is promoted by AflQ1.

Indexed as

Aspartic AcidBacterial ProteinsAnti-Bacterial AgentsGene Expression Regulation, BacterialLincomycinStreptomycesAnti-Bacterial AgentsAspartic AcidBacterial ProteinsLincomycinAflQ1-Q2Aspartate metabolismLincomycin biosynthesisStreptomyces lincolnensisTranscriptional regulationTwo-component system

Identifiers

PMID36930277
OpenAlexW4327685850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.